Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation
Antibody-mediated rejection (AMR) is caused by antibodies that recognize donor human leukocyte antigen (HLA) or other targets. As knowledge of AMR pathophysiology has increased, a combination of factors is necessary to confirm the diagnosis and phenotype. However, frequent modifications to the AMR d...
Main Authors: | Roufosse, C, Becker, JU, Rabant, M, Seron, D, Bellini, MI, Böhmig, GA, Budde, K, Diekmann, F, Glotz, D, Hilbrands, L, Loupy, A, Oberbauer, R, Pengel, L, Schneeberger, S, Naesens, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Frontiers Media
2022
|
Similar Items
-
Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
by: Seron, D, et al.
Published: (2022) -
Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
by: Naesens, M, et al.
Published: (2022) -
Alloimmune risk stratification for kidney transplant rejection
by: Bestard, O, et al.
Published: (2022) -
Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
by: Tong, A, et al.
Published: (2022) -
Allograft function as endpoint for clinical trials in kidney transplantation
by: Hilbrands, L, et al.
Published: (2022)